Author: Vitaliy Dadalyan

Novavax (NVAX) Is a Long-Term Coronavirus Play

Vaccine-maker Novavax (NVAX) is a $6.5 billion company with only $18 million in trailing sales and no profits whatsoever -- but "thanks" to the novel coronavirus, that could soon change. Indeed, in one analyst's view, as little as a year from now, vaccinating patients against COVID-19 could turn out to be a billion-dollar business for Novavax -- or more.But first, the bad news.In a note published Thursday, H.C. Wainwright analyst Vernon Bernardino cites "mathematical models we reviewed online" to argue that contrary to what optimists have been saying, "herd immunity" to infection with coronavirus may not be a viable option for ending the pandemic -- at least not in the short term.As Bernardino points out, coronavirus continues raging around the globe. The latest data show 13.2 million infections have been reported globally, and those infections are growing at the rate of 1.4% per day. Part of the reason that coronavirus continues...

Trulieve Continues Organic Growth Across Florida, Announces Port St. Lucie Location

PORT ST. LUCIE, Fla., July 17, 2020 /CNW/ - Trulieve Cannabis Corp. (CSE: TRUL) & (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company based in the United States, announced today the opening of its latest storefront. Opening on Saturday, July 18th, the Port St. Lucie location will be the Company's 52nd dispensary in its home state of Florida and 54th nationwide....